PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Then, C.* ; Herder, C.* ; Heier, M. ; Meisinger, C. ; Koenig, W.* ; Rathmann, W.* ; Sujana, C. ; Roden, M.* ; Bidlingmaier, M.* ; Seissler, J.* ; Thorand, B. ; Peters, A. ; Reincke, M.*

Association of aldosterone with mortality in the general population.

Exp. Clin. Endocrinol. Diabet. 131, 307-313 (2023)
Postprint DOI PMC
Open Access Green
INTRODUCTION: Aldosterone excess is linked to cardiovascular events and mortality as well as to low-grade inflammation in the context of metabolic diseases. Whether mildly elevated aldosterone levels in the general population promote cardiovascular risk is still under debate. We analyzed the association of plasma aldosterone concentrations with incident cardiovascular events, cardiovascular and all-cause mortality as well as with biomarkers of subclinical inflammation in the population-based KORA F4 study. RESEARCH DESIGN AND METHODS: Plasma aldosterone concentrations were measured with an inhouse immunoflurometric assay. The analyses included 2935 participants (n = 1076 for selected biomarkers of subclinical inflammation) with a median follow-up of 8.7 (8.2; 9.1) years. The associations were estimated using Cox proportional hazard and linear regression models adjusted for renin, sex, age, BMI, arterial hypertension, diabetes, estimated glomerular filtration rate, low- and high-density lipoprotein cholesterol, physical activity, smoking, use of angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta blockers, diuretics and calcium channel blockers. RESULTS: Aldosterone was significantly associated with all-cause mortality (hazard ratio per standard deviation increase: 1.20; 95% confidence interval 1.04-1.37), but not with cardiovascular mortality or incident cardiovascular events, nor with biomarkers of subclinical inflammation. CONCLUSIONS: Aldosterone was associated with all-cause mortality, but the previously described associations of excess aldosterone with cardiovascular complications and biomarkers of subclinical inflammation could not be shown in the population-based KORA F4 study.
Impact Factor
Scopus SNIP
Altmetric
1.800
0.000
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter General Population ; Myocardial Infarction ; Renin ; Stroke; Myocardial-infarction; Activation
Sprache englisch
Veröffentlichungsjahr 2023
HGF-Berichtsjahr 2023
ISSN (print) / ISBN 0947-7349
e-ISSN 1439-3646
Zeitschrift Experimental and Clinical Endocrinology & Diabetes
Quellenangaben Band: 131, Heft: 5, Seiten: 307-313 Artikelnummer: , Supplement: ,
Verlag Thieme
Verlagsort Stuttgart
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Epidemiology (EPI)
Independent Research Group Clinical Epidemiology (KEPI)
POF Topic(s) 30202 - Environmental Health
Forschungsfeld(er) Genetics and Epidemiology
PSP-Element(e) G-504090-001
G-504000-006
G-502900-001
G-504000-002
G-504000-010
Förderungen Clinical Cooperation Group Diabetes, Ludwig-Maximilians-University Munchen
Helmholtz Zentrum Munchen
German Diabetes Center
Federal Ministry of Health (Berlin, Germany)
Ministry of Culture and Science of the State of North Rhine Westphalia (Dusseldorf, Germany)
Helmholtz Zentrum Munchen - German Research Center for Environmental Health - German Federal Ministry of Education and Research (BMBF)
State of Bavaria
Virtual Diabetes Institute (Helmholtz Zentrum Munchen)
Deutsche Diabetes Gesellschaft (DDG)
German Research Foundation (DFG)
Else Kroner-Fresenius Stiftung
European Research Council under the European Union
DFG
European Research Council (ERC)
German Federal Ministry of Education and Research (BMBF)
DOI 10.1055/a-2035-6179
WOS ID 000956196400001
Scopus ID 85159648960
PubMed ID 36787884
Erfassungsdatum 2023-02-23
[➜Korrektur melden]